Leerink Partners analyst Tom Smith reiterated an Outperform rating and $73.00 price target on Keros Therapeutics (NASDAQ: KROS).The analyst comments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE